OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)
Shares of OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) gained 4.50% last Friday, but still were at levels unseen since early January of 2017. Share volume was heavy – about 75% over their 30-day daily average of 1.2 million. Over two million shares traded hands with a notional value of over $700,000.
One World Cannabis Ltd. (OWC) is a wholly owned subsidiary of OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) and discovers and develops cannabis-based therapies and treatments for ilnesses including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing proprietary delivery systems for the delivery and dosage of medical-grade cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions. OWC has two divisions – research and consulting. Its research division pursues clinical trials that will evaluate the effectiveness of cannabinoids for the treatment of various medical conditions. OWC’s consulting division assists governments and private entities create and navigate legal cannabis regulatory frameworks on a global basis.
At the beginning of 2017, shares of OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) began rocketing up from under $0.20 per share to, by the end of February, over $3.20 per share. The catalyst for the gains was a number of appointments to key posts in the company followed by the company receiving the Israeli Institutional Review Board’s (IRB) approval to conduct safety testing on its proprietary topical creme compound for the treatment of psoriasis and related skin conditions. That news followed a U.S. SEC 8K filing announcing an extension to the size and scope of its efficacy study on the same compound, which began in November 2106.
However, since that time, OWCP shareholders have lost interest and last week OWCP shares began trading under $0.40 per share. Some observers believe that OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) may have a tough time creating a commercially viable product to generate revenues. Cannabinoid-based creams to treat skin ailments have existed for some time but without scientific study to back them up. OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is now pursuing clinical trials that would, hopefully, confirm the safety and efficacy of such a treatment. However, should One World Cannabis prove the science, what is to stop existing cannabinoid-based creams from piggy-backing on the results for a fraction of the cost as they had no such expense to absorb?
I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.
Don’t miss out! Stay informed on $OWCP and receive breaking news on other hot stocks by signing up for our free newsletter!
About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.